The most appropriate next step in management is delivery of the baby in this woman with preeclampsia without features of severe disease. Preeclampsia is classically defined as new-onset hypertension after 20 weeks of pregnancy with proteinuria (≥300 mg/24 h or a urine protein-creatinine ratio ≥300 mg/g). Delivery of the baby is the definitive treatment for preeclampsia. In patients with preeclampsia and severe disease, generally defined as severe hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥110 mm Hg), thrombocytopenia (platelet count <100,000/µL [100 × 10⁹/L]), kidney dysfunction (serum creatinine concentration >1.1 mg/dL [97.2 µmol/L] or doubling of the serum creatinine concentration in the absence of other kidney disease), impaired liver function (elevated blood concentrations of liver aminotransferases to twice the normal concentration), pulmonary edema, or cerebral or visual symptoms, management decisions are usually made based on the balance of fetal and maternal risk with the implications of preterm delivery. In women with preeclampsia without severe features, delivery at 37 weeks has been shown to optimize both maternal and neonatal outcomes (such as fetal growth restriction, abruption placentae, hemorrhage due to thrombocytopenia, seizures, cerebral hemorrhage, pulmonary edema, and kidney injury) and is the most appropriate next step in managing this patient.

Treatment of mild hypertension in preeclampsia has not been shown to alter the course of disease or improve fetal outcomes. Therefore, antihypertensive treatment is generally reserved for patients with preeclampsia with severe hypertension, which is not present in this patient.

There is evidence that low-dose aspirin therapy may be beneficial in reducing the occurrence of preeclampsia in moderate- to high-risk women. However, it does not have a role in treating preeclampsia or eclampsia.

Glucocorticoids are used to accelerate fetal lung maturation if delivery is contemplated before the 34th week of pregnancy but do not directly affect outcomes in preeclampsia. Therefore, their use is not indicated in this patient.

Because of the benefit of delivery at 37 weeks' gestation in women with preeclampsia, continued monitoring beyond this time is not optimal.